Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,903,003
  • Shares Outstanding, K 54,810
  • Annual Sales, $ 5,420 K
  • Annual Income, $ -267,270 K
  • 36-Month Beta 1.66
  • Price/Sales 352.48
  • Price/Cash Flow 0.00
  • Price/Book 5.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.14 +28.86%
on 04/11/17
39.34 -7.83%
on 04/28/17
+6.46 (+21.68%)
since 03/28/17
3-Month
26.26 +38.08%
on 02/13/17
39.34 -7.83%
on 04/28/17
+5.43 (+17.61%)
since 01/27/17
52-Week
13.70 +164.67%
on 04/29/16
63.73 -43.10%
on 09/28/16
+22.46 (+162.75%)
since 04/28/16

Most Recent Stories

More News
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician...

HSKA : 108.25 (+2.88%)
SRPT : 36.26 (+4.44%)
GILD : 68.55 (-0.04%)
REGN : 388.49 (+5.97%)
Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments

-- First quarter 2017 EXONDYS 51 total net revenues of $16.3 million --

SRPT : 36.26 (+4.44%)
Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 27, 2017 / Sarepta Therapeutics, Inc. (NASDAQ: SRPT) will be discussing their earnings results in their Q1 Earnings Call to be held April 27, 2017 at 4:30 PM Eastern Time....

SRPT : 36.26 (+4.44%)
Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock?

Investors in Sarepta Therapeutics, Inc. (SRPT) need to pay close attention to the stock based on moves in the options market lately.

SRPT : 36.26 (+4.44%)
Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc. (SRPT)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) ("Sarepta" or "the...

SRPT : 36.26 (+4.44%)
Today's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax

NEW YORK, NY / ACCESSWIRE / April 6, 2017 / Sarepta recently presented clinical trial data at the MDA Scientific conference and received some unexpected support, while Novovax is looking to meet FDA endpoint...

SRPT : 36.26 (+4.44%)
NVAX : 0.82 (-1.20%)
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular...

SRPT : 36.26 (+4.44%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular...

SRPT : 36.26 (+4.44%)
Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?

Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SRPT : 36.26 (+4.44%)
Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company's Strategic and Scientific Advisory Board

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular...

SRPT : 36.26 (+4.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Support & Resistance

2nd Resistance Point 41.07
1st Resistance Point 38.67
Last Price 36.26
1st Support Level 34.53
2nd Support Level 32.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.